Novocure (NVCR) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Novocure (NVCR) Misses Q2 EPS by 8c

Novocure Reports Second Quarter 2022 Financial Results

July 28, 2022 7:00 AM EDT

Quarterly net revenues of $140.9 million, a 6% increase year-over-year

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

The second quarter was a period of solid progress, further solidifying the fundamentals of our business, said William Doyle, Novocures Executive Chairman. We generated $141 million in net revenues in the quarter, released promising data from our... More